Faron Pharmaceuticals: Faron Pharmaceuticals Ltd: Termination of Liquidity Provision Service

Faron Pharmaceuticals OyAnnouncement

06/05/2026 07:00

Faron Pharmaceuticals Ltd | Company announcement | May 06, 2026 at 09:00:00
EEST

Faron has terminated the liquidity providing agreement with Lago Kapital

TURKU, FINLAND – Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a
clinical-stage biopharmaceutical company focused on developing novel
immunotherapies, announces that it has terminated the liquidity provision
agreement with Lago Kapital Oy, with the termination taking effect on 5 June
2026.

The Company estimates that the current liquidity of the shares in the Company
is sufficient without additional liquidity providers.

For more information, please contact:

+-------------------------------------+--------------------------------------+
| IR Partners, Finland                |                                      |
| (Media)                             |                                      |
| Kare Laukkanen                      | +358 50 553 9535 / +44 7 469 766 223 |
|                                     |         kare.laukkanen@irpartners.fi |
+-------------------------------------+--------------------------------------+
| FINN Partners, US                   |                                      |
| (Media)                             |                                      |
| Alyssa Paldo                        |                                      |
|                                     |                     +1 847 791-8085  |
|                                     |        alyssa.paldo@finnpartners.com |
+-------------------------------------+--------------------------------------+
| Cairn Financial Advisers LLP        |                                      |
| (Nominated Adviser and Broker)      |                                      |
| Sandy Jamieson, Jo Turner           |                 +44 (0) 207 213 0880 |
|                                     |                                      |
+-------------------------------------+--------------------------------------+
| Sisu Partners Oy                    |                                      |
| (Certified Adviser on Nasdaq First  |                                      |
| North)                              |                                      |
| Juha Karttunen                      |                  +358 (0)40 555 4727 |
| Jukka Järvelä                       |                  +358 (0)50 553 8990 |
+-------------------------------------+--------------------------------------+

About Faron Pharmaceuticals Ltd
Faron (AIM: FARN, First North: FARON) is a global, clinical-stage
biopharmaceutical company, focused on tackling cancers via novel
immunotherapies. Its mission is to bring the promise of immunotherapy to a
broader population by uncovering novel ways to control and harness the power
of the immune system. The Company’s lead asset is bexmarilimab, a novel
anti-Clever-1 humanized antibody, with the potential to remove
immunosuppression of cancers through reprogramming myeloid cell
function. Bexmarilimab is being investigated in Phase I/II clinical trials as
a potential therapy for patients with hematological cancers in combination
with other standard treatments. Further information is available
at www.faron.com (http://www.faron.com/)

About BEXMAB
The BEXMAB study is an open-label Phase I/II clinical trial
investigating bexmarilimab in combination with standard of care (SoC) in the
aggressive hematological malignancies of acute myeloid leukemia (AML) and
myelodysplastic syndrome (MDS). The primary objective is to determine the
safety and tolerability of bexmarilimab in combination with SoC (azacitidine)
treatment. Directly targeting Clever-1 could limit the replication capacity of
cancer cells, increase antigen presentation, ignite an immune response, and
allow current treatments to be more effective. Clever-1 is highly expressed in
both AML and MDS and associated with therapy resistance, limited T cell
activation and poor outcomes.

About bexmarilimab
Bexmarilimab is Faron’s wholly owned, investigational immunotherapy designed
to overcome resistance to existing treatments and optimize clinical outcomes,
by targeting myeloid cell function and igniting the immune
system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on
macrophages leading to tumor growth and metastases (i.e. helps cancer evade
the immune system). By targeting the Clever-1 receptor on
macrophages, bexmarilimab alters the tumor microenvironment, reprogramming
macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1)
one, upregulating interferon production and priming the immune system to
attack tumors and sensitizing cancer cells to standard of care